Concepts (216)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 5 | 2023 | 138 | 2.120 |
Why?
|
| Coronary Disease | 9 | 2015 | 49 | 1.540 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2020 | 57 | 1.340 |
Why?
|
| Cardiovascular Diseases | 6 | 2020 | 296 | 1.320 |
Why?
|
| Cisplatin | 2 | 2023 | 60 | 1.300 |
Why?
|
| Secondary Prevention | 5 | 2020 | 48 | 1.180 |
Why?
|
| Cardiology | 5 | 2021 | 45 | 1.160 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2021 | 240 | 1.120 |
Why?
|
| Cardiac Rehabilitation | 4 | 2021 | 6 | 1.020 |
Why?
|
| Lung Neoplasms | 3 | 2021 | 540 | 1.020 |
Why?
|
| Acrylamides | 2 | 2020 | 3 | 0.770 |
Why?
|
| Aniline Compounds | 2 | 2020 | 30 | 0.770 |
Why?
|
| Heart Failure | 7 | 2021 | 141 | 0.720 |
Why?
|
| Exercise Test | 3 | 2018 | 112 | 0.700 |
Why?
|
| Humans | 38 | 2023 | 23495 | 0.690 |
Why?
|
| Carboplatin | 1 | 2021 | 24 | 0.670 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2021 | 5 | 0.670 |
Why?
|
| Benzimidazoles | 1 | 2021 | 9 | 0.670 |
Why?
|
| Paclitaxel | 1 | 2021 | 49 | 0.660 |
Why?
|
| Standard of Care | 1 | 2020 | 11 | 0.660 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2021 | 236 | 0.640 |
Why?
|
| Biological Specimen Banks | 1 | 2019 | 5 | 0.620 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2019 | 15 | 0.600 |
Why?
|
| Life Style | 3 | 2019 | 167 | 0.560 |
Why?
|
| Cardiorespiratory Fitness | 1 | 2018 | 15 | 0.560 |
Why?
|
| Lipocalin-2 | 1 | 2018 | 2 | 0.550 |
Why?
|
| Cystatin C | 1 | 2018 | 3 | 0.550 |
Why?
|
| Mutation | 1 | 2019 | 329 | 0.540 |
Why?
|
| Acute Kidney Injury | 1 | 2018 | 34 | 0.540 |
Why?
|
| Antineoplastic Agents | 1 | 2019 | 197 | 0.530 |
Why?
|
| Practice Guidelines as Topic | 2 | 2018 | 236 | 0.520 |
Why?
|
| Apoptosis | 2 | 2022 | 201 | 0.520 |
Why?
|
| Hydrocarbons, Fluorinated | 1 | 2017 | 2 | 0.510 |
Why?
|
| Taxoids | 1 | 2017 | 11 | 0.510 |
Why?
|
| ErbB Receptors | 3 | 2023 | 53 | 0.490 |
Why?
|
| Cell Proliferation | 1 | 2017 | 165 | 0.490 |
Why?
|
| Aged | 19 | 2023 | 7709 | 0.480 |
Why?
|
| Neoplasms | 1 | 2018 | 220 | 0.460 |
Why?
|
| Middle Aged | 16 | 2021 | 8096 | 0.420 |
Why?
|
| Patient Education as Topic | 2 | 2013 | 121 | 0.420 |
Why?
|
| Myocardial Ischemia | 1 | 2014 | 44 | 0.410 |
Why?
|
| Vulnerable Populations | 1 | 2013 | 17 | 0.410 |
Why?
|
| Risk Reduction Behavior | 1 | 2013 | 37 | 0.400 |
Why?
|
| Breast Neoplasms | 1 | 2017 | 376 | 0.390 |
Why?
|
| Male | 18 | 2023 | 12823 | 0.390 |
Why?
|
| Coronary Artery Disease | 2 | 2017 | 124 | 0.380 |
Why?
|
| Acute Coronary Syndrome | 3 | 2021 | 10 | 0.380 |
Why?
|
| Depression | 2 | 2015 | 383 | 0.360 |
Why?
|
| Female | 17 | 2021 | 13305 | 0.350 |
Why?
|
| Critical Pathways | 1 | 2011 | 19 | 0.340 |
Why?
|
| Program Evaluation | 3 | 2017 | 103 | 0.340 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2011 | 18 | 0.330 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2011 | 273 | 0.320 |
Why?
|
| Prognosis | 4 | 2021 | 737 | 0.310 |
Why?
|
| Chest Pain | 1 | 2009 | 20 | 0.300 |
Why?
|
| Mass Screening | 1 | 2011 | 162 | 0.300 |
Why?
|
| Australia | 8 | 2021 | 21 | 0.300 |
Why?
|
| Models, Statistical | 1 | 2009 | 116 | 0.300 |
Why?
|
| Smartphone | 2 | 2021 | 14 | 0.300 |
Why?
|
| Medication Adherence | 1 | 2009 | 49 | 0.290 |
Why?
|
| Risk Factors | 9 | 2019 | 2026 | 0.290 |
Why?
|
| Exercise Therapy | 2 | 2021 | 85 | 0.280 |
Why?
|
| Young Adult | 4 | 2021 | 1724 | 0.270 |
Why?
|
| Quality of Life | 4 | 2021 | 570 | 0.250 |
Why?
|
| Death, Sudden | 1 | 2006 | 7 | 0.250 |
Why?
|
| Adult | 7 | 2021 | 7090 | 0.220 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2018 | 40 | 0.210 |
Why?
|
| Prospective Studies | 5 | 2018 | 1528 | 0.200 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2023 | 30 | 0.200 |
Why?
|
| Laryngeal Neoplasms | 1 | 2023 | 28 | 0.200 |
Why?
|
| Cetuximab | 1 | 2023 | 5 | 0.200 |
Why?
|
| Aged, 80 and over | 7 | 2019 | 3874 | 0.190 |
Why?
|
| Counseling | 2 | 2017 | 39 | 0.180 |
Why?
|
| Nose Neoplasms | 1 | 2022 | 35 | 0.180 |
Why?
|
| Cell-Derived Microparticles | 1 | 2022 | 5 | 0.180 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 2022 | 59 | 0.180 |
Why?
|
| Risk Assessment | 3 | 2019 | 552 | 0.170 |
Why?
|
| Radiosurgery | 1 | 2021 | 29 | 0.170 |
Why?
|
| Retrospective Studies | 5 | 2023 | 3082 | 0.160 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2022 | 162 | 0.160 |
Why?
|
| Societies, Medical | 2 | 2020 | 118 | 0.160 |
Why?
|
| Comorbidity | 4 | 2021 | 430 | 0.160 |
Why?
|
| Treatment Outcome | 5 | 2021 | 3058 | 0.160 |
Why?
|
| United Kingdom | 1 | 2019 | 40 | 0.150 |
Why?
|
| Blood Circulation | 1 | 2019 | 1 | 0.150 |
Why?
|
| Liquid Biopsy | 1 | 2019 | 4 | 0.150 |
Why?
|
| Circulating Tumor DNA | 1 | 2019 | 5 | 0.150 |
Why?
|
| DNA Mutational Analysis | 1 | 2019 | 51 | 0.150 |
Why?
|
| Walking Speed | 1 | 2019 | 35 | 0.150 |
Why?
|
| Molecular Targeted Therapy | 1 | 2019 | 31 | 0.150 |
Why?
|
| Diastole | 1 | 2019 | 28 | 0.150 |
Why?
|
| Waist Circumference | 1 | 2019 | 35 | 0.150 |
Why?
|
| Obesity, Abdominal | 1 | 2019 | 19 | 0.150 |
Why?
|
| Stroke Volume | 1 | 2019 | 41 | 0.150 |
Why?
|
| Ventricular Function, Left | 1 | 2019 | 34 | 0.150 |
Why?
|
| Biomarkers | 2 | 2019 | 486 | 0.150 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2019 | 8 | 0.140 |
Why?
|
| Infection Control | 1 | 2020 | 168 | 0.140 |
Why?
|
| Predictive Value of Tests | 3 | 2019 | 445 | 0.140 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2019 | 67 | 0.140 |
Why?
|
| Peptide Fragments | 1 | 2019 | 59 | 0.140 |
Why?
|
| Mouth | 1 | 2018 | 12 | 0.140 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 79 | 0.140 |
Why?
|
| American Heart Association | 1 | 2018 | 15 | 0.140 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 82 | 0.140 |
Why?
|
| Pharynx | 1 | 2018 | 11 | 0.140 |
Why?
|
| Pandemics | 1 | 2020 | 207 | 0.140 |
Why?
|
| Hemorrhage | 1 | 2018 | 73 | 0.140 |
Why?
|
| Glomerular Filtration Rate | 1 | 2018 | 35 | 0.140 |
Why?
|
| Aspirin | 1 | 2018 | 50 | 0.130 |
Why?
|
| Exercise | 1 | 2021 | 404 | 0.130 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2017 | 4 | 0.130 |
Why?
|
| Geriatric Assessment | 1 | 2018 | 171 | 0.130 |
Why?
|
| Signal Transduction | 1 | 2019 | 392 | 0.130 |
Why?
|
| Coronary Vessels | 1 | 2017 | 33 | 0.130 |
Why?
|
| Caspases | 1 | 2017 | 22 | 0.130 |
Why?
|
| Health Behavior | 3 | 2021 | 140 | 0.130 |
Why?
|
| United States | 3 | 2018 | 1814 | 0.130 |
Why?
|
| Tumor Cells, Cultured | 1 | 2017 | 125 | 0.130 |
Why?
|
| Body Mass Index | 1 | 2019 | 402 | 0.130 |
Why?
|
| Blotting, Western | 1 | 2017 | 132 | 0.130 |
Why?
|
| Telephone | 2 | 2014 | 23 | 0.120 |
Why?
|
| Patient Compliance | 3 | 2016 | 146 | 0.120 |
Why?
|
| Biomarkers, Tumor | 1 | 2017 | 200 | 0.110 |
Why?
|
| Calcium | 1 | 2017 | 370 | 0.100 |
Why?
|
| Depressive Disorder | 2 | 2015 | 163 | 0.100 |
Why?
|
| New Zealand | 3 | 2020 | 10 | 0.090 |
Why?
|
| Evidence-Based Medicine | 2 | 2011 | 139 | 0.090 |
Why?
|
| Affect | 1 | 2011 | 57 | 0.080 |
Why?
|
| Family Practice | 1 | 2009 | 13 | 0.080 |
Why?
|
| Bayes Theorem | 1 | 2009 | 32 | 0.080 |
Why?
|
| Medical Audit | 1 | 2009 | 5 | 0.080 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2009 | 16 | 0.080 |
Why?
|
| Hospitals, Teaching | 1 | 2009 | 29 | 0.080 |
Why?
|
| Telemedicine | 1 | 2011 | 85 | 0.070 |
Why?
|
| Unnecessary Procedures | 1 | 2009 | 26 | 0.070 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2009 | 26 | 0.070 |
Why?
|
| Program Development | 1 | 2009 | 44 | 0.070 |
Why?
|
| Electrocardiography | 1 | 2009 | 92 | 0.070 |
Why?
|
| Exercise Tolerance | 2 | 2021 | 30 | 0.070 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2009 | 43 | 0.070 |
Why?
|
| Prevalence | 1 | 2009 | 389 | 0.070 |
Why?
|
| Incidence | 2 | 2019 | 642 | 0.060 |
Why?
|
| Myocardial Revascularization | 1 | 2006 | 16 | 0.060 |
Why?
|
| Life Expectancy | 1 | 2006 | 22 | 0.060 |
Why?
|
| Time Factors | 1 | 2009 | 1276 | 0.060 |
Why?
|
| Survival Rate | 1 | 2006 | 320 | 0.060 |
Why?
|
| Cholesterol | 2 | 2003 | 60 | 0.060 |
Why?
|
| Hypercholesterolemia | 2 | 2002 | 20 | 0.060 |
Why?
|
| Printing, Three-Dimensional | 1 | 2023 | 6 | 0.050 |
Why?
|
| Immobilization | 1 | 2023 | 11 | 0.050 |
Why?
|
| Laryngectomy | 1 | 2023 | 16 | 0.050 |
Why?
|
| Neck | 1 | 2023 | 23 | 0.050 |
Why?
|
| Salvage Therapy | 1 | 2023 | 33 | 0.050 |
Why?
|
| Patient-Centered Care | 1 | 2003 | 41 | 0.050 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2023 | 47 | 0.050 |
Why?
|
| Chemoradiotherapy | 1 | 2023 | 57 | 0.050 |
Why?
|
| Victoria | 2 | 2019 | 8 | 0.050 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2022 | 31 | 0.050 |
Why?
|
| Biology | 1 | 2022 | 7 | 0.050 |
Why?
|
| Anticholesteremic Agents | 1 | 2002 | 14 | 0.050 |
Why?
|
| Ipilimumab | 1 | 2021 | 3 | 0.040 |
Why?
|
| Length of Stay | 1 | 2023 | 298 | 0.040 |
Why?
|
| Walk Test | 1 | 2021 | 10 | 0.040 |
Why?
|
| Early Medical Intervention | 1 | 2021 | 13 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 202 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2022 | 369 | 0.040 |
Why?
|
| Health Promotion | 1 | 2002 | 123 | 0.040 |
Why?
|
| Recovery of Function | 1 | 2021 | 254 | 0.040 |
Why?
|
| Consensus | 1 | 2020 | 82 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2022 | 594 | 0.040 |
Why?
|
| Symptom Assessment | 1 | 2019 | 17 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 69 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 122 | 0.040 |
Why?
|
| Echocardiography | 1 | 2019 | 68 | 0.040 |
Why?
|
| ROC Curve | 1 | 2019 | 124 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2018 | 96 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2018 | 130 | 0.030 |
Why?
|
| Sex Factors | 1 | 2019 | 403 | 0.030 |
Why?
|
| Insurance, Health | 1 | 2017 | 17 | 0.030 |
Why?
|
| Propensity Score | 1 | 2017 | 33 | 0.030 |
Why?
|
| Residence Characteristics | 1 | 2019 | 179 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2018 | 374 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2017 | 109 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2016 | 1492 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2017 | 227 | 0.030 |
Why?
|
| Age Factors | 1 | 2019 | 656 | 0.030 |
Why?
|
| Disease Management | 1 | 2017 | 98 | 0.030 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2017 | 72 | 0.030 |
Why?
|
| Text Messaging | 1 | 2016 | 13 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2016 | 89 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2017 | 507 | 0.030 |
Why?
|
| Independent Living | 1 | 2018 | 240 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 807 | 0.030 |
Why?
|
| Anxiety | 1 | 2015 | 143 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2019 | 1500 | 0.030 |
Why?
|
| Social Support | 1 | 2015 | 180 | 0.030 |
Why?
|
| Hypolipidemic Agents | 2 | 2003 | 23 | 0.020 |
Why?
|
| Cardiovascular Agents | 1 | 2011 | 22 | 0.020 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2011 | 36 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2011 | 53 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2011 | 210 | 0.020 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 2006 | 13 | 0.020 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2006 | 30 | 0.020 |
Why?
|
| Aftercare | 1 | 2006 | 22 | 0.020 |
Why?
|
| Physical Examination | 1 | 2006 | 94 | 0.010 |
Why?
|
| Palliative Care | 1 | 2006 | 108 | 0.010 |
Why?
|
| Allied Health Personnel | 1 | 2003 | 7 | 0.010 |
Why?
|
| Nursing Staff, Hospital | 1 | 2003 | 26 | 0.010 |
Why?
|
| Europe | 1 | 2002 | 52 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2002 | 126 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2002 | 228 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2002 | 297 | 0.010 |
Why?
|
| Hypertension | 1 | 2002 | 169 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2002 | 150 | 0.010 |
Why?
|
| Obesity | 1 | 2002 | 288 | 0.010 |
Why?
|